311 resultados para Glioblastoma Multiforme
Resumo:
Microvascular density (MVD) may be an additional prognostic marker for astrocytomas, but the heterogeneity of these tumors limits its use. Thus, imaging examinations such as SPECT-MIBI (2-methoxyisobutyl isonitrile) may take on an indirect role in astrocytoma evaluation. The aim of this study was to evaluate MVD in astrocytomas using immunohistochemistry with anti-CD34 monoclonal antibodies. The relationship between the immunohistochemical data and the parameters obtained from SPECT-MIBI was evaluated. This cross-sectional study evaluated 48 patients with brain tumors including low-grade astrocytomas (LGAs), anaplastic astrocytomas (AAs) and glioblastoma multiformes (GBMs). Patients had been admitted to the Hospital de Cancer de Barretos - Fundação Pio XII, and underwent brain SPECT-MIBI prior to any treatment. MVD was determined under an optical microscope by counting microvessels on slides from each case. SPECT-MIBI images were analyzed visually and semiquantitatively. GBMs, AAs and LGAs represented 50, 16.7 and 33.3% of the total sample, respectively. There were 13 normal and 35 abnormal SPECT-MIBI images. Significant differences in MVD were found between AA and LGA cases (p=0.040), but not between normal and abnormal SPECT-MIBI. The mean counts from SPECT-MIBI were not correlated with MVD. Among the GBM cases, there were no significant findings, except for an increased likelihood of abnormal histological test results. MVD was related to histological grade (in AA and LGA cases) but was not correlated with SPECT-MIBI.
Resumo:
Diffuse large cell non Hodgkin's lymphoma associated with chronic lymphoid leukemia (CLL), or Richter's syndrome, is a rare and serious complication. Isolated Richter's syndrome in the central nervous system is very rare; only 12 cases have been reported. We describe a 74-year-old patient with diffuse large cell non Hodgkin's lymphoma in the right frontal region with the appearance of multiform glioblastoma.
Resumo:
Some modifying factors may determine the risk of brain tumors. Until now, it could not be attempted to identify people at risk and also to improve significantly disease progression. Current therapy consists of surgical resection, followed by radiation therapy and chemotherapy. Despite of these treatments, the prognosis for patients is poor. In this review, we highlight general aspects concerning genetic alterations in brain tumors, namely astrocytomas, glioblastomas, oligodendrogliomas, medulloblastomas and ependymomas. The influence of these genetic alterations in patients' prognosis is discussed. Mutagen sensivity is associated with cancer risk. The convincing studies that linked DNA damages and DNA repair alterations with brain tumors are also described. Another important modifying factor is immunity. General immune response against cancer, tumor microenvironment and immune response, mechanisms of tumor escape, CNS tumor immunology, immune defects that impair anti-tumor systemic immunity in brain tumor patients and local immunosuppressive factors within CNS are also reviewed. New hope to treatment perspectives, as dendritic-cell-based vaccines is summarized too. Concluding, it seems well established that there is association between brain tumor risk and mutagen sensivity, which is highly heritable. Primary brain tumors cause depression in systemic host immunity; local immunosuppressive factors and immunological characteristics of tumor cells may explain the poor prognosis and DNA damages responses can alert immune system. However, it is necessary to clarify if individuals with both constitutional defects in immune functions and genetic instability have higher risk of developing brain tumors. Cytogenetic prospective studies and gene copy number variations analysis also must be performed in peripheral lymphocytes from brain tumor patients. © 2011 Bentham Science Publishers Ltd.
Resumo:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Resumo:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Resumo:
Pós-graduação em Química - IQ
Resumo:
Pós-graduação em Psicologia - FCLAS
Resumo:
Hepatitis C is associated with autoimmune diseases, hepatocellular carcinoma,and extrahepatic manifestations that, in conjunction, may seriously compromise the patient's quality of life. We herein describe a case of chronic hepatitis C with oral manifestations and discuss some implications for diagnosis and treatment. A 63-year-old woman complaining of spontaneous bleeding of the oral mucosa presented with bilateral asymmetric ulcers surrounded by white papules and striae on the buccal mucosa. Her medical history revealed leucopenia, thrombocytopenia, and skin lesions associated with chronic hepatitis C. Propranolol and ranitidine had recently been prescribed. Lichen planus, lichenoid reaction, and erythema multiforme were considered in the differential diagnosis. Histopathological analysis revealed lymphocytic infiltrate in a lichenoid pattern. The lesions partially healed after 1 week and completely regressed after 6 months, despite the maintenance of all medications; no recurrence was observed. The final diagnosis was oral lichen planus associated with hepatitis C. Chronic hepatitis C may present oral manifestations, which demand adjustments in dental treatment planning. Medication side effects may interfere with the clinical presentation and course of the disease and should be accounted for in the differential diagnosis. The possibility of spontaneous remission of oral lichen planus should always be considered, especially when putative etiological factors of a lichenoid lesion are withdrawn in an attempt to differentiate oral lichen planus from lichenoid lesions. This case emphasizes the importance of recognizing the extrahepatic manifestations of hepatitis C as a cause of increased morbidity.
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
The gene XRCC3 (X-ray cross complementing group 3) has the task of repairing damage that occurs when there is recombination between homologous chromosomes. Repair of recombination between homologous chromosomes plays an important role in maintaining genome integrity, although it is known that double-strand breaks are the main inducers of chromosomal aberrations. Changes in the XRCC3 protein lead to an increase in errors in chromosome segregation due to defects in centrosomes, resulting in aneuploidy and other chromosomal aberrations, such as small increases in telomeres. We examined XRCC3 Thr241Met polymorphism using PCR-RFLP in 80 astrocytoma and glioblastoma samples. The individuals of the control group (N = 100) were selected from the general population of the Sao Paulo State. Odds ratio and 95%CI were calculated using a logistic regression model. Patients who had the allele Met of the XRCC3 Thr241Met polymorphism had a significantly increased risk of tumor development (odds ratio = 3.13; 95% confidence interval = 1.50-6.50). There were no significant differences in overall survival of patients. We suggest that XRCC3 Thr241Met polymorphism is involved in susceptibility for developing astrocytomas and glioblastomas.
Resumo:
N-4-Phenyl 2-acetylpyridine thiosemicarbazone (H2Ac4Ph; N-(phenyl)-2-(1-(pyridin-2-yl)ethylidene) hydrazinecarbothioamide) and its N-4-ortho-, -meta- and -para-fluorophenyl (H2Ac4oFPh, H2Ac4mFPh, H2Ac4pFPh), N-4-ortho-, -meta- and -para-chlorophenyl (H2Ac4oClPh, H2Ac4mClPh, H2Ac4pClPh), N-4-ortho-, -meta- and -para-iodophenyl (H2Ac4oIPh, H2Ac4mIPh, H2Ac4pIPh) and N-4-ortho-, -meta- and -para-nitrophenyl (H2Ac4oNO(2)Ph, H2Ac4mNO(2)Ph, H2Ac4pNO(2)Ph) derivatives were assayed for their cytotoxicity against human malignant breast (MCF-7) and glioma (T98G and U87) cells. The compounds were highly cytotoxic against the three cell lineages (IC50: MCF-7, 52-0.16 nM; T98G, 140-1.0 nM; U87, 160-1.4 nM). All tested thiosemicarbazones were more cytotoxic than etoposide and did not present any haemolytic activity at up to 10(-5) M. The compounds were able to induce programmed cell death. H2Ac4pClPh partially inhibited tubulin assembly at high concentrations and induced cellular microtubule disorganization. (C) 2012 Elsevier Ltd. All rights reserved.
Resumo:
OBJECTIVE: The aim of the current study was to monitor the migration of superparamagnetic iron oxide nanoparticle (SPION)-labeled C6 cells, which were used to induce glioblastoma tumor growth in an animal model, over time using magnetic resonance imaging (MRI), with the goal of aiding in tumor prognosis and therapy. METHODS: Two groups of male Wistar rats were used for the tumor induction model. In the first group (n=3), the tumors were induced via the injection of SPION-labeled C6 cells. In the second group (n=3), the tumors were induced via the injection of unlabeled C6 cells. Prussian Blue staining was performed to analyze the SPION distribution within the C6 cells in vitro. Tumor-inducing C6 cells were injected into the right frontal cortex, and subsequent tumor monitoring and SPION detection were performed using T2- and T2*-weighted MRI at a 2T field strength. In addition, cancerous tissue was histologically analyzed after performing the MRI studies. RESULTS: The in vitro qualitative evaluation demonstrated adequate distribution and satisfactory cell labeling of the SPIONs. At 14 or 21 days after C6 injection, a SPION-induced T2- and T2*-weighted MRI signal reduction was observed within the lesion located in the left frontal lobe on parasagittal topography. Moreover, histological staining of the tumor tissue with Prussian Blue revealed a broad distribution of SPIONs within the C6 cells. CONCLUSION: MRI analyses exhibit potential for monitoring the tumor growth of C6 cells efficiently labeled with SPIONs.
Resumo:
La regolazione dell’espressione genica è un processo molto complesso e finemente controllato da fattori multipli, tra i quali quelli epigenetici hanno richiamato l’attenzione nell’ultima decade. I meccanismi di regolazione epigenetica comprendono la metilazione del DNA a livello delle isole CpG nella regione del promotore del gene e le modifiche istoniche post-traduzionali, quali acetilazioni e metilazioni. Questa serie di elementi di regolazione concorre a determinare uno stato di impacchettamento della cromatina più o meno rilassato, che influenzerà la trascrizione di geni critici, per esempio nello sviluppo o nelle neoplasie. Gli ambiti nei quali lo studio del profilo epigenetico ha assunto maggiore rilievo sono effettivamente quello oncologico e quello del differenziamento di cellule staminali, due contesti nei quali si è svolto il mio programma di Dottorato, nel quale ho seguito in parallelo più progetti presentati nella tesi in modo indipendente. La ricerca in campo tumorale è centrata sull’indagine di nuovi marcatori e sull’individuazione di profili epigenetici specifici per un determinato tumore che possano aiutare la diagnostica precoce, la classificazione e la sorveglianza dell’evoluzione clinica della neoplasia. In questo contesto si inserisce il progetto finalizzato alla costruzione di quadri associativi di metilazione in due tumori cerebrali, il glioblastoma (GBM) e l’oligodendroglioma (ODG). La casistica di GBM e di ODG in dotazione è stata valutata dal punto di vista della metilazione dei promotori di geni (MGMT, EMP3,..) con funzioni oncosoppressive e trovati ipermetilati anche in altri tumori o localizzati in regioni citologicamente instabili, per poter correlare questi dati con la risposta terapeutica nel caso del GBM o con i dati di perdita di eterozigosità (LOH) 1p19q nel caso dell’ODG. Parallelamente all’individuazione di marcatori epigenetici in ambito oncologico, la ricerca si sta muovendo anche nell’indagine di nuove potenziali terapie farmacologiche antitumorali su base epigenetica. In questo contesto, con lo scopo di approfondire le relazioni tra i meccanismi alla base della regolazione epigenetica, ci si è riproposti di valutare la correlazione tra il meccanismo di metilazione/demetilazione del DNA e quello di acetilazione/deacetilazione istonica e la loro vicendevole influenza nel determinare silenziamento genico piuttosto che riattivazione dell’espressione di geni ipermetilati. Sono stati usati farmaci epigenetici demetilanti, quali Azacitidina e Decitabina, inibitori della istone deacetilasi, quali la Tricostatina A, e inibitori della via di sintesi di molecole, le poliammine, coinvolte nella regolazione dell’espressione genica con modalità ancora da precisare in modo definitivo. Sebbene i meccanismi di regolazione epigenetica vengano studiati per lo più nel cancro, a causa delle gravi conseguenze che una loro disregolazione porta in termini di silenziamento di geni oncosoppressori, essi sono implicati fisiologicamente anche nel differenziamento di cellule staminali. Gli ultimi due progetti trattati nella tesi si contestualizzano in questo ambito. In particolare viene presentata la messa a punto di una metodologia di immunoprecipitazione sequenziale della cromatina finalizzata all’individuazione di due modificazioni istoniche associate alla stessa regione di DNA. Le modifiche hanno riguardato i marcatori rappresenatativi di cromatina trascrizionalmente repressa H3K27me3 (trimetilazione della Lys27 dell’istone H3) e di cromatina trascrizionalmente attiva H3K24me2 (dimetilazione della Lys4 dell’istone H3) che definiscono i domini detti bivalenti, associati a geni che codificano per fattori di trascrizione che regolano lo sviluppo in cellule embrionali staminali, mantenendoli pronti per un veloce indirizzamento verso l’ attivazione trascrizionale. Il ruolo che la regolazione epigenetica svolge durante il differenziamento di cellule staminali non è ancora noto con precisione. È chiaro però che la memoria della linea cellulare verso la quale si differenzia una cellula staminale adulta, implica l’utilizzo di modifiche epigenetiche, quali la metilazione del DNA e correlati pattern di metilazione e acetilazione istonica. L’ultimo progetto, trattato, è stato finalizzato a verificare il coinvolgimento dell’epigenetica e in particolare della metilazione dei promotori di fattori trascrizionali precocemente attivati durante il differenziamento verso il fenotipo muscolare cardiaco di cellule staminali umane derivate da tessuto adiposo (ADSCs).
Resumo:
Gliomas are the most common primary brain tumours. Despite advances in surgical techniques, postoperative supportive care, radiation and adjuvant systemic therapy, the life expectancy of patients with high grade glioma has remained essentially poor. Furthermore differential diagnosis among astrocytomas, oligodendrogliomas and oligoastrocytomas is very challenging and subject to inter-observer variability. The purpose of the research was: 1) to investigate a series of high grade and low grade gliomas at gene and protein (immunohistochemistry) levels to disclose possible genetic portraits of malignancy; 2) to verify the utility of Nogo-A, Olig-2 and synaptophysin in providing a correct histological diagnosis of oligodendroglioma and to investigate a possible complementary role in selecting the best areas suitable for detecting 1p/19q codeletion using FISH analysis; 3) to study the role of microRNA in high grade gliomas. In order to obtain these goals large series of brain tumors were studied with DNA microarrays, immunohistochemistry and RT-PCR The results demonstrated that: - Overexpression of IGFBP-2 and CDC20 is highly related to glioblastomas and their immunopositivity can be useful for the identification of glioblastoma in small biopsies. - Nogo-A is the most useful and specific marker in differentiating oigodendrogliomas from other gliomas. Furthermore, using a Nogo-A driven FISH analysis, it is possible to identify a larger number of 1p19q codeletions in gliomas. - microRNAs can be studied in paraffin embedded tissues better than in fresh tissues. A series of six microRNA, significatively deregulated in glioblastomas, may represent a genetic signature with prognostic and predictive value and could constitute candidates for novel anti-cancer therapeutics.
Resumo:
ZusammenfassungDer humane kationische Aminosäure-Transporter hCAT-1 (CAT für cationic amino acid transporter) gehört zur Familie der Na+- und pH-unabhängigen Transporter für basische Aminosäuren (BAS). Die vorliegende Arbeit befasst sich mit unterschiedlichen Aspekten des hCAT-1-vermittelten Transportes, die in zwei Teilabschnitten behandelt werden. Im ersten Abschnitt wurden die Transporteigenschaften von hCAT-1-exprimierenden X. laevis-Oozyten mit Hilfe von elektrophysiologischen Methoden untersucht und mit denen der Isoformen hCAT-2A und -2B verglichen. Dabei zeigte sich, dass es durch die Expression von hCAT-2A und -2B in Oozyten zur Bildung eines BAS-Potentiales kommt, jedoch nicht durch die Expression von hCAT-1. Hierfür dürfte die hohe Transstimulierbarkeit des hCAT-1-Proteins verantwortlich sein. Obwohl das Membranpotential einer Zelle die Akkumulation von BAS durch die hCAT-Proteine beeinflusst, war bei sehr hohen extrazellulären BAS-Konzentrationen die Akkumulation durch hCAT-1 und -2B im Gegensatz zu hCAT-2A nicht vom Membranpotential abhängig, da unter diesen Bedingungen der Efflux limitierend wirkte. Mit Hilfe der voltage clamp-Methode wurden die L-Arginin-induzierten Maximalströme (Vmax) und die Leitfähigkeiten der hCAT-Proteine bestimmt. Die so ermittelten Vmax-Werte sind nur halb so groß wie die durch Flux-Studien bestimmten. Daher muss von einem Gegentransport an positiver Ladung (Substrat) ausgegangen werden. Weiterhin konnte gezeigt werden, dass die hCAT-Isoformen zwei unterschiedliche Leitfähigkeitszustände für BAS besitzen, die von der intrazellulären BAS-Konzentration abhängig sind. Eine Leitfähigkeitszunahme durch Zugabe von extrazellulärem L-Arginin konnte bei allen hCAT-Isoformen in depletierten Oozyten beobachtet werden. In BAS-beladenen Oozyten führte die Zugabe von L-Arginin dagegen zu keiner (hCAT-1 und hCAT-2B) bzw. zu einer geringen (hCAT-2A) Zunahme der Leitfähigkeit der Transporter. Im Substratgleichgewicht jedoch nahm die Leitfähigkeit der drei untersuchten hCAT-Isoformen in Abhängigkeit von der Substratkonzentration zu. Überraschenderweise wurden für die untersuchten hCAT-Isoformen Leck-Ströme in Abwesenheit von BAS nachgewiesen. An hCAT-2B-exprimierenden Oozyten wurde eine erhöhte Leitfähigkeit für K+-Ionen gezeigt. Die physiologische Bedeutung dieser Kanalfunktion ist jedoch noch völlig ungeklärt. Im zweiten Abschnitt wurde der Mechanismus der Proteinkinase C (PKC)-vermittelten Inhibition der hCAT-1-Transportaktivität untersucht. Hierfür wurden hCAT-1.EGFP-Konstrukte in Oozyten und in U373MG Glioblastom-Zellen exprimiert. Mit Hilfe konfokaler Mikroskopie und Western-Blot-Analysen von biotinylierten Zelloberflächen-Proteinen wurde gezeigt, dass die PKC-vermittelte Reduktion der hCAT-1-Transportaktivität auf einer Reduktion der hCAT-Expression an der Zelloberfläche beruht. Ähnliche Ergebnisse wurden auch mit dem endogen in humanen DLD-1 Kolonkarzinom-Zellen exprimierten hCAT-1 erzielt. Der PKC-Effekt war auch noch nach Entfernung der putativen PKC-Erkennungsstellen am hCAT-1-Protein vorhanden. Daher reguliert die PKC die hCAT-1-Transportaktivität vermutlich über einen indirekten Mechanismus, d. h. nicht über eine direkte Phosphorylierung des hCAT-1-Proteins. Die Veränderung der Zelloberflächenexpression stellt einen neuen Regulationsmechanismus für die CAT-Proteine dar, der erklären kann, warum sich Modifikationen in der CAT-Proteinexpression oft nicht in entsprechenden Veränderungen der Transportaktivität widerspiegeln.